FDA Purple Book · Reference family
lebrikizumab-lbkz (Ebglyss)
lebrikizumab-lbkz is an FDA-licensed reference biologic from Eli Lilly and Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
351(a)BLA 761306
Ebglyss lebrikizumab-lbkz
Eli Lilly and Company
- Approved
- Sep 13, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for lebrikizumab-lbkz, in chronological order.
Reference approval
Approval date of the reference lebrikizumab-lbkz product.
1 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for lebrikizumab-lbkz (Ebglyss)?
No 351(k) biosimilars or interchangeable biosimilars referencing lebrikizumab-lbkz are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.